\-\ Texto\\:\\ \ \(0\)\
\-\ left\\ breast\\ distinctly\\ larger\\ than\\ the\\ right\\ breast\\.\\ \\ there\\ is\\ diffuse\\ erythema\\,\\ brawny\\ edema\\ and\\ peau\\ d\\â\\€\\™orange\\ covering\\ approximately\\ two\\-thirds\\ of\\ the\\ breast\\.\\ \\ no\\ distinct\\ breast\\ masses\\ or\\ nipple\\ discharge\\.\\ \\ multiple\\ mobile\\ congruent\\ masses\\ were\\ palpated\\ in\\ the\\ left\\ axilla\\.\\ normal\\ right\\ breast\\ and\\ axilla\\.\\ \\ left\\ supraclavicular\\ palpable\\ mass\\.\ \(0\)\
\-\ the\\ patient\\ is\\ currently\\ being\\ treated\\ with\\ neoadjuvant\\ chemotherapy\\.\\ \\ this\\ will\\ be\\ followed\\ by\\ mastectomy\\,\\ post\\ surgical\\ radiation\\ treatments\\ and\\ maintenance\\ chemotherapy\\.\ \(0\)\
\-\ initial\\ mri\\:\ \(0\)\
\-\ \\	axial\\ gradient\\ echo\\ demonstrates\\ \\ asymmetric\\ enlargement\\ of\\ the\\ fibroglandular\\ tissue\\ of\\ the\\ left\\ breast\\,\\ most\\ prominent\\ in\\ the\\ posterior\\-lateral\\ aspect\\.\\ \\ no\\ distinct\\ masses\\ identified\\.\\ \\ three\\ distinct\\,\\ enlarged\\ and\\ rounded\\ left\\ axillary\\ lymph\\ nodes\\.\\ axial\\ post\\ gadolinium\\ gre\\ show\\ diffuse\\ heterogeneous\\ enhancement\\ throughout\\ most\\ of\\ the\\ fibroglandular\\ tissue\\ of\\ the\\ left\\ breast\\.\\ \\ the\\ axillary\\ lymph\\ nodes\\ and\\ the\\ skin\\ demonstrate\\ abnormal\\ enhancement\\.\\ sagittal\\ post\\ gadolinium\\ images\\ lateral\\ to\\ the\\ nipple\\ demonstrates\\ diffuse\\ enlargement\\ and\\ abnormal\\ enhancement\\ of\\ the\\ fibroglandular\\ tissue\\,\\ consistent\\ with\\ a\\ diffuse\\ infiltrating\\ process\\.\\ \\ no\\ discrete\\ masses\\ identified\\.\\ \\ images\\ at\\ the\\ level\\ of\\ the\\ nipple\\ demonstrate\\ significant\\ nipple\\ retraction\\.\\ \\ \\ \ \(0\)\
\-\ post\\ neoadjuvant\\ chemotherapy\\ mri\\:\ \(0\)\
\-\ \\ \\ \\ \\ \\ axial\\ gradient\\ echo\\ shows\\ near\\ resolution\\ of\\ the\\ asymmetric\\ enlargement\\ of\\ the\\ left\\ breast\\ fibroglandular\\ tissue\\.\\ \ \(0\)\
\-\ axial\\ post\\ gadolinium\\ shows\\ there\\ has\\ been\\ near\\ resolution\\ of\\ the\\ asymmetric\\ enlargement\\ of\\ the\\ left\\ breast\\ fibroglandular\\ tissue\\.\\ \\ there\\ is\\ residual\\ heterogeneous\\ enhancement\\ throughout\\ the\\ fibroglandular\\ tissue\\,\\ although\\ much\\ improved\\.\\ \\ the\\ lymph\\ nodes\\ have\\ decreased\\ in\\ size\\.\\ \\ sagittal\\ post\\ gadolinium\\ demonstate\\ the\\ nipple\\ retraction\\ has\\ resolved\\.\\ \\ the\\ skin\\ is\\ much\\ improved\\ but\\ still\\ remains\\ residually\\ thickened\\ and\\ enhanced\\.\ \(0\)\
\-\ inflammatory\\ breast\\ carcinoma\ \(0\)\
\-\ inflammatory\\ breast\\ cancer\ \(3\)\
\-\ mastitis\ \(11\)\
\-\ lymphoma\ \(373\)\
\-\ 46\\ y\\/o\\ woman\\ had\\ a\\ normal\\ screening\\ mammogram\\ in\\ june\\ 2002\\.\\ \\ in\\ november\\ 2002\\ she\\ noticed\\ left\\ axillary\\ lymphadenopathy\\,\\ but\\ an\\ excisional\\ biopsy\\ showed\\ reactive\\ lymph\\ node\\,\\ no\\ carcinoma\\.\ \(0\)\
\-\ in\\ july\\ 2003\\,\\ she\\ noticed\\ left\\ supraclavicular\\ lymphadenopathy\\.\ \(0\)\
\-\ in\\ august\\ 2003\\ patient\\ began\\ to\\ notice\\ left\\ breast\\ enlargement\\,\\ diffuse\\ skin\\ thickening\\ and\\ erythema\\,\\ and\\ upper\\ extremity\\ edema\\.\ \(0\)\
\-\ this\\ woman\\ had\\ a\\ normal\\ screening\\ mammogram\\ in\\ june\\ 2002\\.\\ \\ in\\ november\\ 2002\\ the\\ patient\\ noticed\\ left\\ axillary\\ lymphadenopathy\\.\\ \\ she\\ underwent\\ an\\ excisional\\ biopsy\\,\\ which\\ showed\\ reactive\\ lymph\\ node\\,\\ no\\ carcinoma\\.\\ \\ in\\ july\\ 2003\\,\\ she\\ noticed\\ left\\ supraclavicular\\ lymphadenopathy\\.\\ \\ in\\ august\\ 2003\\ patient\\ began\\ to\\ notice\\ left\\ breast\\ enlargement\\,\\ diffuse\\ skin\\ thickening\\ and\\ erythema\\,\\ and\\ upper\\ extremity\\ edema\\.\\ \\ a\\ mammogram\\ performed\\ at\\ that\\ time\\ showed\\ interval\\ increase\\ in\\ size\\ of\\ axillary\\ lymph\\ nodes\\ and\\ a\\ diffuse\\ increase\\ in\\ attenuation\\ of\\ left\\ breast\\ compared\\ to\\ the\\ right\\.\\ \\ yet\\ no\\ discrete\\ or\\ suspicious\\ mass\\ could\\ be\\ seen\\ in\\ either\\ side\\.\\ \\ in\\ october\\ 2003\\,\\ had\\ excisional\\ biopsy\\ of\\ left\\ supraclavicular\\ node\\ and\\ a\\ punch\\ biopsy\\ of\\ the\\ skin\\ of\\ the\\ breast\\.\\ \\ results\\ of\\ those\\ biopsies\\ showed\\ metastatic\\ cancer\\ consistent\\ with\\ breast\\ primary\\ in\\ the\\ lymph\\ node\\ and\\ invasive\\ ductal\\ carcinoma\\ with\\ involvement\\ of\\ the\\ skin\\ lymphatics\\ \\(inflammatory\\ carcinoma\\)\\ on\\ the\\ skin\\ biopsy\\.\\ \\ mri\\ was\\ performed\\ at\\ the\\ time\\ to\\ evaluate\\ for\\ primary\\ lesion\\ not\\ seen\\ on\\ mammogram\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ breast\\:\\ 0\\.09393096294467194\ \(0\)\
\-\ fibroglandular\\:\\ 0\\.06983876051960851\ \(0\)\
\-\ nipple\\:\\ 0\\.04727978403801797\ \(0\)\
\-\ lymph\\:\\ 0\\.04496610216501402\ \(0\)\
\-\ axillary\\:\\ 0\\.04321351167663744\ \(0\)\
\-\ skin\\:\\ 0\\.0427838036250891\ \(0\)\
\-\ 2003\\:\\ 0\\.03997886263424077\ \(0\)\
\-\ supraclavicular\\:\\ 0\\.039181902141356306\ \(0\)\
\-\ enlargement\\:\\ 0\\.037883445882515035\ \(0\)\
\-\ noticed\\:\\ 0\\.03480360296145226\ \(0\)\
\-\ diffuse\\:\\ 0\\.03372262931587934\ \(0\)\
\-\ mammogram\\:\\ 0\\.03321273443036802\ \(0\)\
\-\ excisional\\:\\ 0\\.03251277179001401\ \(0\)\
\-\ gadolinium\\:\\ 0\\.030192510161405898\ \(0\)\
\-\ post\\:\\ 0\\.030065195900249093\ \(0\)\
\-\ node\\:\\ 0\\.029126582089594552\ \(0\)\
\-\ nodes\\:\\ 0\\.028750028799741062\ \(0\)\
\-\ left\\:\\ 0\\.02848730783680938\ \(0\)\
\-\ distinct\\:\\ 0\\.02836787042281078\ \(0\)\
\-\ biopsy\\:\\ 0\\.028228056253601124\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.02706692643332896\ \(0\)\
\-\ neoadjuvant\\:\\ 0\\.024649139093595077\ \(0\)\
\-\ erythema\\:\\ 0\\.023465910095671724\ \(0\)\
\-\ asymmetric\\:\\ 0\\.023195973909801295\ \(0\)\
\-\ 2002\\.\\:\\ 0\\.023003579494790462\ \(0\)\
\-\ tissue\\:\\ 0\\.022630404340252444\ \(0\)\
\-\ carcinoma\\:\\ 0\\.022550536964765985\ \(0\)\
\-\ november\\:\\ 0\\.022506255872352762\ \(0\)\
\-\ axilla\\:\\ 0\\.02228046584696567\ \(0\)\
\-\ masses\\:\\ 0\\.02151651693106955\ \(0\)\
\-\ notice\\:\\ 0\\.02115465254390074\ \(0\)\
\-\ showed\\:\\ 0\\.02087004296404988\ \(0\)\
\-\ june\\:\\ 0\\.020844106514332578\ \(0\)\
\-\ july\\:\\ 0\\.020557473214011805\ \(0\)\
\-\ retraction\\:\\ 0\\.02016506905886161\ \(0\)\
\-\ august\\:\\ 0\\.019590951070678153\ \(0\)\
\-\ gradient\\:\\ 0\\.01928466392640638\ \(0\)\
\-\ discrete\\:\\ 0\\.01833779562702373\ \(0\)\
\-\ axial\\:\\ 0\\.01816604451447204\ \(0\)\
\-\ she\\:\\ 0\\.017868053195189366\ \(0\)\
\-\ 2002\\:\\ 0\\.01740180148072613\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.017111428967267403\ \(0\)\
\-\ enhancement\\:\\ 0\\.0170613688351809\ \(0\)\
\-\ echo\\:\\ 0\\.016558922054001775\ \(0\)\
\-\ inflammatory\\:\\ 0\\.01655483767705041\ \(0\)\
\-\ residually\\:\\ 0\\.016416235426380817\ \(0\)\
\-\ began\\:\\ 0\\.0161150169617667\ \(0\)\
\-\ improved\\:\\ 0\\.015160470374686213\ \(0\)\
\-\ brawny\\:\\ 0\\.015125458553829707\ \(0\)\
\-\ congruent\\:\\ 0\\.015125458553829707\ \(0\)\
\-\ reactive\\:\\ 0\\.015064557912479825\ \(0\)\
\-\ much\\:\\ 0\\.01473261087376099\ \(0\)\
\-\ distinctly\\:\\ 0\\.014370402486589178\ \(0\)\
\-\ peau\\:\\ 0\\.014370402486589178\ \(0\)\
\-\ orange\\:\\ 0\\.014370402486589178\ \(0\)\
\-\ demonstate\\:\\ 0\\.0138346816812786\ \(0\)\
\-\ near\\:\\ 0\\.013771041383797927\ \(0\)\
\-\ resolution\\:\\ 0\\.013726702826977374\ \(0\)\
\-\ screening\\:\\ 0\\.013575547221334625\ \(0\)\
\-\ edema\\:\\ 0\\.013502365862744642\ \(0\)\
\-\ increase\\:\\ 0\\.01334975719594753\ \(0\)\
\-\ posterior\\-lateral\\:\\ 0\\.013079625614038068\ \(0\)\
\-\ lymphatics\\:\\ 0\\.01279256661994634\ \(0\)\
\-\ sagittal\\:\\ 0\\.012694028500954859\ \(0\)\
\-\ in\\:\\ 0\\.012555597173638881\ \(0\)\
\-\ mastitis\\:\\ 0\\.012324569546797538\ \(0\)\
\-\ punch\\:\\ 0\\.012128367469222443\ \(0\)\
\-\ throughout\\:\\ 0\\.011913397863314438\ \(0\)\
\-\ two\\-thirds\\:\\ 0\\.01178884874148696\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.011702775258081957\ \(0\)\
\-\ extremity\\:\\ 0\\.011639325771480215\ \(0\)\
\-\ maintenance\\:\\ 0\\.011501789747395231\ \(0\)\
\-\ october\\:\\ 0\\.011501789747395231\ \(0\)\
\-\ identified\\:\\ 0\\.011372316726950918\ \(0\)\
\-\ covering\\:\\ 0\\.011253127936176381\ \(0\)\
\-\ gre\\:\\ 0\\.011033792674246432\ \(0\)\
\-\ mri\\:\\ 0\\.010968021535835865\ \(0\)\
\-\ thickening\\:\\ 0\\.010788173443923098\ \(0\)\
\-\ size\\:\\ 0\\.010669928757462836\ \(0\)\
\-\ cancer\\:\\ 0\\.010462440463183483\ \(0\)\
\-\ had\\:\\ 0\\.010300836978998371\ \(0\)\
\-\ biopsies\\:\\ 0\\.010278736607005902\ \(0\)\
\-\ palpated\\:\\ 0\\.00964233196320319\ \(0\)\
\-\ no\\:\\ 0\\.009613901125182145\ \(0\)\
\-\ mastectomy\\:\\ 0\\.009455956807603593\ \(0\)\
\-\ primary\\:\\ 0\\.009427874349704641\ \(0\)\
\-\ treatments\\:\\ 0\\.009207294996384743\ \(0\)\
\-\ abnormal\\:\\ 0\\.00907669363245777\ \(0\)\
\-\ mobile\\:\\ 0\\.009058239674832533\ \(0\)\
\-\ time\\:\\ 0\\.00898920382584474\ \(0\)\
\-\ yet\\:\\ 0\\.008920236002293015\ \(0\)\
\-\ performed\\:\\ 0\\.008873662313695787\ \(0\)\
\-\ shows\\:\\ 0\\.008749995157277016\ \(0\)\
\-\ infiltrating\\:\\ 0\\.008642702335327487\ \(0\)\
\-\ \\,\\:\\ 0\\.008569964830156212\ \(0\)\
\-\ 46\\:\\ 0\\.008426553040629623\ \(0\)\
\-\ remains\\:\\ 0\\.008279461027000888\ \(0\)\
\-\ invasive\\:\\ 0\\.007995772526848152\ \(0\)\
\-\ the\\:\\ 0\\.007980871184008193\ \(0\)\
\-\ d\\:\\ 0\\.007936017751147035\ \(0\)\
\-\ residual\\:\\ 0\\.007897220568832618\ \(0\)\
\-\ rounded\\:\\ 0\\.007840499512064072\ \(0\)\
\-\ consistent\\:\\ 0\\.007803717947229807\ \(0\)\
\-\ interval\\:\\ 0\\.007803623111140087\ \(0\)\
\-\ discharge\\:\\ 0\\.007714505753267396\ \(0\)\
\-\ resolved\\:\\ 0\\.007714505753267396\ \(0\)\
\-\ upper\\:\\ 0\\.00768000188219262\ \(0\)\
\-\ larger\\:\\ 0\\.0076630131437133734\ \(0\)\
\-\ suspicious\\:\\ 0\\.0076630131437133734\ \(0\)\
\-\ still\\:\\ 0\\.007580235187343107\ \(0\)\
\-\ ductal\\:\\ 0\\.007500980784328589\ \(0\)\
\-\ normal\\:\\ 0\\.0074838684614474925\ \(0\)\
\-\ woman\\:\\ 0\\.007351593845396299\ \(0\)\
\-\ most\\:\\ 0\\.007347616915188366\ \(0\)\
\-\ demonstrate\\:\\ 0\\.007323844101799034\ \(0\)\
\-\ those\\:\\ 0\\.007240716459607623\ \(0\)\
\-\ thickened\\:\\ 0\\.007135776168078514\ \(0\)\
\-\ there\\:\\ 0\\.0071045561813686525\ \(0\)\
\-\ demonstrates\\:\\ 0\\.006952034270589147\ \(0\)\
\-\ either\\:\\ 0\\.0069306670822341454\ \(0\)\
\-\ enhanced\\:\\ 0\\.006809056098234579\ \(0\)\
\-\ but\\:\\ 0\\.0067877217915587994\ \(0\)\
\-\ compared\\:\\ 0\\.006735607807636262\ \(0\)\
\-\ prominent\\:\\ 0\\.006531193159339466\ \(0\)\
\-\ at\\:\\ 0\\.006467950574478397\ \(0\)\
\-\ evaluate\\:\\ 0\\.006432451132694735\ \(0\)\
\-\ results\\:\\ 0\\.006423728880716288\ \(0\)\
\-\ attenuation\\:\\ 0\\.006397804600420928\ \(0\)\
\-\ patient\\:\\ 0\\.006380573042207732\ \(0\)\
\-\ currently\\:\\ 0\\.006305722150860442\ \(0\)\
\-\ seen\\:\\ 0\\.006289115884795866\ \(0\)\
\-\ process\\:\\ 0\\.00612675136840729\ \(0\)\
\-\ images\\:\\ 0\\.006105265891803925\ \(0\)\
\-\ has\\:\\ 0\\.005976536202958204\ \(0\)\
\-\ could\\:\\ 0\\.0058706851840419965\ \(0\)\
\-\ involvement\\:\\ 0\\.005832288001169118\ \(0\)\
\-\ palpable\\:\\ 0\\.005639890209683036\ \(0\)\
\-\ being\\:\\ 0\\.0055452290070773895\ \(0\)\
\-\ side\\:\\ 0\\.0055129357574749925\ \(0\)\
\-\ underwent\\:\\ 0\\.005460327812808602\ \(0\)\
\-\ enlarged\\:\\ 0\\.0054294619560223585\ \(0\)\
\-\ although\\:\\ 0\\.005374169982451776\ \(0\)\
\-\ three\\:\\ 0\\.005364290928020318\ \(0\)\
\-\ followed\\:\\ 0\\.005334964378731418\ \(0\)\
\-\ initial\\:\\ 0\\.005272964885063888\ \(0\)\
\-\ radiation\\:\\ 0\\.00522206936603787\ \(0\)\
\-\ right\\:\\ 0\\.005037048654248138\ \(0\)\
\-\ aspect\\:\\ 0\\.0049986814422408885\ \(0\)\
\-\ will\\:\\ 0\\.004978549382456503\ \(0\)\
\-\ approximately\\:\\ 0\\.004923310663976877\ \(0\)\
\-\ be\\:\\ 0\\.004907846269437352\ \(0\)\
\-\ show\\:\\ 0\\.004884834142442507\ \(0\)\
\-\ treated\\:\\ 0\\.004763223158442941\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.004756101936025057\ \(0\)\
\-\ decreased\\:\\ 0\\.004731389949207746\ \(0\)\
\-\ and\\:\\ 0\\.004692972216482418\ \(0\)\
\-\ level\\:\\ 0\\.00458638552634438\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0045478559299617985\ \(0\)\
\-\ a\\:\\ 0\\.004431282701883813\ \(0\)\
\-\ mass\\:\\ 0\\.004426297977458341\ \(0\)\
\-\ y\\/o\\:\\ 0\\.0044071304093475615\ \(0\)\
\-\ an\\:\\ 0\\.004400986459161005\ \(0\)\
\-\ been\\:\\ 0\\.004329226982242069\ \(0\)\
\-\ significant\\:\\ 0\\.004279044974030211\ \(0\)\
\-\ \\:\\:\\ 0\\.004209589631250149\ \(0\)\
\-\ is\\:\\ 0\\.004188385686292184\ \(0\)\
\-\ than\\:\\ 0\\.0041695509402574936\ \(0\)\
\-\ metastatic\\:\\ 0\\.004005790323307431\ \(0\)\
\-\ to\\:\\ 0\\.003976425590716818\ \(0\)\
\-\ of\\:\\ 0\\.003905155334010785\ \(0\)\
\-\ or\\:\\ 0\\.0037300661041478863\ \(0\)\
\-\ were\\:\\ 0\\.0036131961577093503\ \(0\)\
\-\ this\\:\\ 0\\.0035796544257509612\ \(0\)\
\-\ have\\:\\ 0\\.0034458809652981224\ \(0\)\
\-\ lateral\\:\\ 0\\.0034388604201574494\ \(0\)\
\-\ multiple\\:\\ 0\\.003351594047447428\ \(0\)\
\-\ surgical\\:\\ 0\\.0033449194976749603\ \(0\)\
\-\ lesion\\:\\ 0\\.003241257404097681\ \(0\)\
\-\ which\\:\\ 0\\.002970474091699346\ \(0\)\
\-\ that\\:\\ 0\\.00274856746472779\ \(0\)\
\-\ on\\:\\ 0\\.0026960559119755235\ \(0\)\
\-\ by\\:\\ 0\\.0026496664864895246\ \(0\)\
\-\ not\\:\\ 0\\.0022994761112512764\ \(0\)\
\-\ \\.\\:\\ 0\\.002247642881396226\ \(0\)\
\-\ was\\:\\ 0\\.001840367825351372\ \(0\)\
\-\ for\\:\\ 0\\.001357743293561853\ \(0\)\
\-\ \\(\\:\\ 0\\.0013451801233591444\ \(0\)\
\-\ \\)\\:\\ 0\\.0013287480300061547\ \(0\)\
\-\ with\\:\\ 0\\.0008715394867030892\ \(0\)\
